mavacamten HCM Camzyos
Selected indexed studies
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet, 2020) [PMID:32871100]
- Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial. (JAMA Cardiol, 2023) [PMID:37639243]
- Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM. (JACC Heart Fail, 2025) [PMID:39909647]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. (2020) pubmed
- Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. (2023) pubmed
- Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. (2024) pubmed
- Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. (2024) pubmed
- Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial. (2023) pubmed
- Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM. (2025) pubmed
- Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy - The HORIZON-HCM Study. (2024) pubmed
- Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM. (2025) pubmed
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. (2021) pubmed
- Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis. (2021) pubmed